PUBLISHER: AnalystView Market Insights | PRODUCT CODE: 2172227
PUBLISHER: AnalystView Market Insights | PRODUCT CODE: 2172227
Blood Compatible Polymers Market size was valued at US$ 3,690.7 Million in 2025, expanding at a CAGR of 10.3% from 2026 to 2033.
Blood-compatible polymers are defined as those polymers that can be utilized in contact with blood without inducing any adverse effects on the blood, such as blood clotting, anemia, and so forth. These types of polymers are always hydrophilic polymers, and their examples include anti-coagulant polymers and heparin. Apart from this, there are certain properties of the surfaces of these polymers that prevent protein and platelet adhesion. Blood-compatible polymers find use in the manufacture of vascular grafts, catheters, blood bags, and numerous other medical devices. Polymers that are used for the manufacture of medical devices are polyurethanes, polyethylene glycol, heparin-coated polymers, and numerous others. Nowadays there is a need for more advanced polymers with modified surfaces and biomimetics. Hence, blood-compatible polymers are vital for safe blood-contacting medical devices, preventing adverse reactions and improving patient outcomes.
Blood Compatible Polymers Market- Market Dynamics
Increasing Cardiovascular Disease Prevalence To Drive Market Demand
The increasing incidence of cardiovascular disease will help to propel the growth of the market of blood-compatible polymers in the future. The growing incidence of cardiovascular disease is set to help in boosting the market of blood-compatible polymers, as they will be used in making cardiovascular implants, stents, artificial heart valves, and vascular grafts. In July 2025, according to the World Health Organization (WHO), the number of death cases due to CVDs across the world is estimated to be 19.8 million, accounting for around 32% of total death cases. The study also reveals that 85% of CVD deaths are linked with heart attack and stroke. Additionally, over 75% of CVD deaths worldwide are in low and middle-income countries. In addition, approximately 38% of the 18 million death cases caused by non-communicable diseases before reaching 70 years are due to CVDs. Thus, the increasing cases of cardiovascular disease will propel the demand for blood-compatible polymers in advanced medical implants.
The Global Blood Compatible Polymers Market is segmented on the basis of Product Type, Application, End User, and Region.
Among the given applications, cardiovascular devices hold a prominent share of the Blood Compatible Polymers market. The demand for blood-compatible polymers comes as a result of the increase in the need for materials that will help avoid the formation of clots in order to make the device more effective and safe. In February 2026, Lubrizol launched the Tolerathane(TM) Thermoplastic Polyurethane (TPU) medical grade, which can be used to manufacture implantable medical devices like cardiac leads, structural heart implants, and percutaneous catheters. They ensure better biostability, softness, and mechanical resistance. Therefore, advanced biocompatible materials provide innovations in cardiovascular medical devices.
Blood Compatible Polymers Market- Geographical Insights
North America holds a key position in the Blood Compatible Polymers market due to the availability of advanced healthcare organizations and a high incidence rate of cardiovascular diseases. For instance, in May 2026, according to the World Health Systems Facts Org., the public coverage of essential health services in Canada reached 100%. Canada has a high number of physicians per 1,000 of the population, which is 2.72, and the number of nurses per 1,000 populations is 10.05. In addition, the number of beds in hospitals per 1,000 of the population is 2.5, and the health care expenditure equals 11.30% of GDP. Therefore, the presence of highly developed healthcare infrastructure and the high prevalence of cardiovascular diseases contribute to the development of the Blood Compatible Polymers market in North America.
Europe's market growth is supported by strict biocompatibility requirements set by the IVDR and MDR that will include detailed testing of the polymeric materials prior to their entry into the market. For instance, in July 2026, according to the NIH Gov, the EU Medical Device Regulation (MDR) on the medical device supply in Germany was estimated in order to find out its influence on safety and availability. It has been concluded that the delay in certification and withdrawal from the market can cause an extra death rate of 163-1,884 per year and an additional mortality impact of 700-4,200 deaths once. As per the official German statistics, there are around 17 device-related deaths per year, while the world-wide statistic claims that the figure can be higher, up to 2,500 deaths per year. Thus, the proper implementation of MDR regulation allows ensuring the availability of medical devices in Germany and improving patient safety in the EU.
Blood compatible polymers are mainly provided by established specialty chemical and medical technology companies such as B. Braun Melsungen AG, W. L. Gore & Associates, Inc., Eastman Chemical Company, DSM Biomedical, and Asahi Kasei Corporation. These companies specialize in blood-compatible biomaterials, high-performance polymers, and materials science to create medical devices and health care products. In July 2025, B. Braun added seven premixed injection products to its lineup of Heparin Sodium Injection products, which can be attributed to blood-compatible products because of their healthcare application, even though it is more of a pharmaceutical product range increase.
In April 2025, DSM-Firmenich Biomedical and Peijia Medical partnered to design heart valve polymers. Polymer heart valve materials are being developed using ultra-high molecular weight polyethylene and thermoplastic polyurethane. The two companies will work together to manufacture medical devices and heart valve polymers, which can help people suffering from cardiovascular diseases.